Maynard Paton discusses AstraZeneca's (LSE: AZN) third-quarter results.
Maynard Paton and Nate Weisshaar analyse AstraZeneca's (LSE: AZN) recent Q3 results and what they mean for private investors. Suggesting that not all is doom and gloom following the announcement of a 15% drop in sales and decline in profits as well, the Fools believe Astra is still a contrarian favourite while also offering a decent dividend income percentage. To hear a broader and considerably better view than the results would have you think, click the link below to watch the video...
It's no secret that blue-chip Footsie stalwarts like AstraZeneca are favoured by market-trouncing City investor Neil Woodford. To find out the investing logic behind his purchases, plus the names of seven other large-cap companies he is backing today, then download this free report while it remains available.
Click below to watch Nate and Maynard's video
Further Motley Fool investment opportunities:
> Neither Nate nor Maynard own shares in any of the companies mentioned.